{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:48Z","timestamp":1793647668581,"version":"4.5.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Although indications for anti-interleukin 6 (IL-6) receptor antibody (anti-IL6R) therapy continue to expand, the clinical features of bloodstream infection (BSI) in anti-IL6R recipients remain poorly characterized. We investigated the prevalence, clinical and microbiological features of BSI among the anti-IL6R recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, retrospective study of BSI episodes occurring within 90 days of anti-IL6R administration between 2005 and 2024. Complicated BSI was defined as the presence of either (1) infection-related mortality, (2) remote or localized suppurative complications, (3) embolic stroke, or (4) recurrence within 90 days. Associations between clinical variables and complicated BSI were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 922 anti-IL6R recipients, 47 patients (5%) developed BSI. Demographics varied by indication for anti-IL6R, and 89% received concomitant immunosuppressive therapy. Catheter-related bloodstream (23%) and intra-abdominal (21%) were most common foci, followed by bone and joint (14%). At presentation, fever was absent in 53%, and serum CRP was within normal range in 30%. Septic shock occurred in 26%, and all-cause 30-day mortality was 19%. Complicated BSI occurred in 22 episodes (47%). In univariate analysis, underlying rheumatic disease, community acquisition, onset within 21 days of anti-IL6R administration, and\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      or\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      etiology were associated with complicated BSI, whereas higher pulse rate at presentation and Pitt bacteremia score\u2009\u2265\u20094 were inversely associated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In anti-IL6R recipients, BSI frequently lacked typical signs such as fever but often resulted in severe outcomes. Clinicians should maintain a high index of suspicion for complicated BSI in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02938-0","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:52:46Z","timestamp":1787061166000},"page":"2895-2906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-0375","authenticated-orcid":false,"given":"Koh","family":"Shinohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-5158","authenticated-orcid":false,"given":"Kentaro","family":"Tochitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-8823","authenticated-orcid":false,"given":"Yoshiki","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-3652","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuchido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-3269","authenticated-orcid":false,"given":"Masaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-8944","authenticated-orcid":false,"given":"Yasufumi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-6145","authenticated-orcid":false,"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2938_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50:1007\u201323. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.026.","journal-title":"Immunity"},{"key":"2938_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2213-2600(21)00103-X","volume":"9","author":"OJ McElvaney","year":"2021","unstructured":"McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9:643\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(21)00103-X.","journal-title":"Lancet Respir Med"},{"key":"2938_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","volume":"180","author":"A Puel","year":"2008","unstructured":"Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008;180:647\u201354. https:\/\/doi.org\/10.4049\/jimmunol.180.1.647.","journal-title":"J Immunol"},{"key":"2938_CR4","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/annrheumdis-2012-202768","volume":"72","author":"T Nanki","year":"2013","unstructured":"Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, Hosoya T, et al. Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections. Ann Rheum Dis. 2013;72:1100\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202768.","journal-title":"Ann Rheum Dis"},{"key":"2938_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","volume":"78","author":"A Pawar","year":"2019","unstructured":"Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78:456\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214367.","journal-title":"Ann Rheum Dis"},{"key":"2938_CR6","doi-asserted-by":"publisher","first-page":"e00035","DOI":"10.1128\/CMR.00035-19","volume":"33","author":"JS Davis","year":"2020","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev. 2020;33:e00035\u201319. https:\/\/doi.org\/10.1128\/CMR.00035-19.","journal-title":"Clin Microbiol Rev"},{"key":"2938_CR7","doi-asserted-by":"publisher","first-page":"bcr2012007413","DOI":"10.1136\/bcr-2012-007413","volume":"2013","author":"MTT Nguyen","year":"2013","unstructured":"Nguyen MTT, P\u00f8denphant J, Ravn P. Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab. BMJ Case Rep. 2013;2013:bcr2012007413. https:\/\/doi.org\/10.1136\/bcr-2012-007413.","journal-title":"BMJ Case Rep"},{"key":"2938_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2169\/internalmedicine.9519-22","volume":"62","author":"K Togitani","year":"2023","unstructured":"Togitani K, Ogasawara F, Arakawa Y, Sugimura N, Miyazaki R, Kojima K. Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease. Intern Med. 2023;62:449\u201352. https:\/\/doi.org\/10.2169\/internalmedicine.9519-22.","journal-title":"Intern Med"},{"key":"2938_CR9","doi-asserted-by":"publisher","first-page":"e8997","DOI":"10.1002\/ccr3.8997","volume":"12","author":"A Lee","year":"2024","unstructured":"Lee A, Aw YTV. Staphylococcus aureus subcapsular splenic abscess and associated empyema in the setting of tocilizumab therapy: A case report. Clin Case Rep. 2024;12:e8997. https:\/\/doi.org\/10.1002\/ccr3.8997.","journal-title":"Clin Case Rep"},{"key":"2938_CR10","doi-asserted-by":"publisher","first-page":"bcr0220125835","DOI":"10.1136\/bcr.02.2012.5835","volume":"2012","author":"Y Yanagawa","year":"2012","unstructured":"Yanagawa Y, Hirano Y, Kato H, Iba T. The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment. BMJ Case Rep. 2012;2012:bcr0220125835. https:\/\/doi.org\/10.1136\/bcr.02.2012.5835.","journal-title":"BMJ Case Rep"},{"key":"2938_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40121-022-00592-1","volume":"11","author":"M Kuwahara","year":"2022","unstructured":"Kuwahara M, Kamigaito M, Nitta S, Hasegawa K, Murakami H, Kobayashi T, et al. Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study. Infect Dis Ther. 2022;11:533\u201341. https:\/\/doi.org\/10.1007\/s40121-022-00592-1.","journal-title":"Infect Dis Ther"},{"key":"2938_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1385\/IR:30:3:261","volume":"30","author":"TW Du Clos","year":"2004","unstructured":"Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30:261\u201377. https:\/\/doi.org\/10.1385\/IR:30:3:261.","journal-title":"Immunol Res"},{"key":"2938_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s15010-024-02375-x","volume":"53","author":"A Killer","year":"2025","unstructured":"Killer A, Gliga S, Massion P, Ackermann C, De Angelis C, Flasshove C, et al. Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID-19 patients treated with tocilizumab. Infection. 2025;53:339\u201348. https:\/\/doi.org\/10.1007\/s15010-024-02375-x.","journal-title":"Infection"},{"key":"2938_CR14","doi-asserted-by":"publisher","first-page":"e0102823","DOI":"10.1128\/jcm.01028-23","volume":"62","author":"EL Palavecino","year":"2024","unstructured":"Palavecino EL, Campod\u00f3nico VL, She RC. Laboratory approaches to determining blood culture contamination rates: an ASM Laboratory Practices Subcommittee report. J Clin Microbiol. 2024;62:e0102823. https:\/\/doi.org\/10.1128\/jcm.01028-23.","journal-title":"J Clin Microbiol"},{"key":"2938_CR15","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","volume":"163","author":"VG Fowler","year":"2003","unstructured":"Fowler VG, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163:2066\u201372. https:\/\/doi.org\/10.1001\/archinte.163.17.2066.","journal-title":"Arch Intern Med"},{"key":"2938_CR16","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s15010-024-02202-3","volume":"52","author":"U Mondal","year":"2024","unstructured":"Mondal U, Warren E, Bookstaver PB, Kohn J, Al-Hasan MN. Incidence and predictors of complications in Gram-negative bloodstream infection. Infection. 2024;52:1725\u201331. https:\/\/doi.org\/10.1007\/s15010-024-02202-3.","journal-title":"Infection"},{"key":"2938_CR17","doi-asserted-by":"publisher","first-page":"ofac653","DOI":"10.1093\/ofid\/ofac653","volume":"9","author":"TW van der Vaart","year":"2022","unstructured":"van der Vaart TW, Prins JM, Soetekouw R, van Twillert G, Veenstra J, Herpers BL, et al. All-Cause and Infection-Related Mortality in Staphylococcus aureus Bacteremia, a Multicenter Prospective Cohort Study. Open Forum Infect Dis. 2022;9:ofac653. https:\/\/doi.org\/10.1093\/ofid\/ofac653.","journal-title":"Open Forum Infect Dis"},{"key":"2938_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/313753","volume":"30","author":"JS Li","year":"2000","unstructured":"Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633\u20138. https:\/\/doi.org\/10.1086\/313753.","journal-title":"Clin Infect Dis"},{"key":"2938_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2016.0289","volume":"315","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:775\u201387. https:\/\/doi.org\/10.1001\/jama.2016.0289.","journal-title":"JAMA"},{"key":"2938_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791\u20137. https:\/\/doi.org\/10.7326\/0003-4819-137-10-200211190-00007.","journal-title":"Ann Intern Med"},{"key":"2938_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"issue":"Suppl 2","key":"2938_CR22","doi-asserted-by":"publisher","first-page":"S294","DOI":"10.1086\/513856","volume":"179","author":"CA Dinarello","year":"1999","unstructured":"Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis. 1999;179(Suppl 2):S294\u2013304. https:\/\/doi.org\/10.1086\/513856.","journal-title":"J Infect Dis"},{"key":"2938_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.1840120517","volume":"12","author":"JV Castell","year":"1990","unstructured":"Castell JV, G\u00f3mez-Lech\u00f3n MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179\u201386. https:\/\/doi.org\/10.1002\/hep.1840120517.","journal-title":"Hepatology"},{"key":"2938_CR24","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","volume":"59","author":"KL Gr\u00f8n","year":"2020","unstructured":"Gr\u00f8n KL, Glintborg B, N\u00f8rgaard M, Mehnert F, \u00d8stergaard M, Dreyer L, et al. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatology (Oxford). 2020;59:1949\u201356. https:\/\/doi.org\/10.1093\/rheumatology\/kez530.","journal-title":"Rheumatology (Oxford)"},{"key":"2938_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","volume":"50","author":"L Campbell","year":"2011","unstructured":"Campbell L, Chen C, Bhagat SS, Parker RA, \u00d6st\u00f6r AJK. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/keq343.","journal-title":"Rheumatology (Oxford)"},{"key":"2938_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","volume":"77","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:905\u201310. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212825.","journal-title":"Ann Rheum Dis"},{"key":"2938_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","volume":"59","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years\u2019 follow-up. Rheumatology (Oxford). 2020;59:292\u2013302. https:\/\/doi.org\/10.1093\/rheumatology\/kez265.","journal-title":"Rheumatology (Oxford)"},{"key":"2938_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76:504\u201310. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209773.","journal-title":"Ann Rheum Dis"},{"key":"2938_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s13054-025-05556-8","volume":"29","author":"T Imaeda","year":"2025","unstructured":"Imaeda T, Oami T, Yokoyama T, Nakagawa S, Ogura H, Shime N, et al. Epidemiology and outcomes of septic shock in Japan: a nationwide retrospective cohort study from a medical claims database by the Japan Sepsis Alliance (JaSA) study group. Crit Care. 2025;29:309. https:\/\/doi.org\/10.1186\/s13054-025-05556-8.","journal-title":"Crit Care"},{"key":"2938_CR30","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.ajic.2018.06.019","volume":"46","author":"H Hattori","year":"2018","unstructured":"Hattori H, Maeda M, Nagatomo Y, Takuma T, Niki Y, Naito Y, et al. Epidemiology and risk factors for mortality in bloodstream infections: A single-center retrospective study in Japan. Am J Infect Control. 2018;46:e75\u20139. https:\/\/doi.org\/10.1016\/j.ajic.2018.06.019.","journal-title":"Am J Infect Control"},{"key":"2938_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/clind\/24.4.584","volume":"24","author":"MP Weinstein","year":"1997","unstructured":"Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584\u2013602. https:\/\/doi.org\/10.1093\/clind\/24.4.584.","journal-title":"Clin Infect Dis"},{"key":"2938_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/cid\/ciae281","volume":"79","author":"CD Russell","year":"2024","unstructured":"Russell CD, Berry K, Cooper G, Sim W, Lee RS, Gan TY, et al. Distinct Clinical Endpoints of Staphylococcus aureus Bacteraemia Complicate Assessment of Outcome. Clin Infect Dis. 2024;79:604\u201311. https:\/\/doi.org\/10.1093\/cid\/ciae281.","journal-title":"Clin Infect Dis"},{"key":"2938_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1128\/JCM.02882-12","volume":"51","author":"A Fern\u00e1ndez-Cruz","year":"2013","unstructured":"Fern\u00e1ndez-Cruz A, Mar\u00edn M, Kestler M, Alcal\u00e1 L, Rodriguez-Cr\u00e9ixems M, Bouza E. The value of combining blood culture and SeptiFast data for predicting complicated bloodstream infections caused by Gram-positive bacteria or Candida species. J Clin Microbiol. 2013;51:1130\u20136. https:\/\/doi.org\/10.1128\/JCM.02882-12.","journal-title":"J Clin Microbiol"},{"key":"2938_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","volume":"69","author":"D Yahav","year":"2019","unstructured":"Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019;69:1091\u20138. https:\/\/doi.org\/10.1093\/cid\/ciy1054.","journal-title":"Clin Infect Dis"},{"key":"2938_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","volume":"392","author":"N Daneman","year":"2025","unstructured":"Daneman N, Rishu A, Pinto R, Rogers BA, Shehabi Y, Parke R, et al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. 2025;392:1065\u201378. https:\/\/doi.org\/10.1056\/NEJMoa2404991.","journal-title":"N Engl J Med"},{"key":"2938_CR36","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","volume":"323","author":"E von Dach","year":"2020","unstructured":"von Dach E, Albrich WC, Brunel A-S, Prendki V, Cuvelier C, Flury D, et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020;323:2160\u20139. https:\/\/doi.org\/10.1001\/jama.2020.6348.","journal-title":"JAMA"},{"key":"2938_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","volume":"28","author":"J Molina","year":"2022","unstructured":"Molina J, Montero-Mateos E, Praena-Segovia J, Le\u00f3n-Jim\u00e9nez E, Natera C, L\u00f3pez-Cort\u00e9s LE, et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. Clin Microbiol Infect. 2022;28:550\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.001.","journal-title":"Clin Microbiol Infect"},{"key":"2938_CR38","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/cid\/ciy1134","volume":"69","author":"N Wald-Dickler","year":"2019","unstructured":"Wald-Dickler N, Spellberg B. Short-course Antibiotic Therapy-Replacing Constantine Units With Shorter Is Better. Clin Infect Dis. 2019;69:1476\u20139. https:\/\/doi.org\/10.1093\/cid\/ciy1134.","journal-title":"Clin Infect Dis"},{"key":"2938_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.diagmicrobio.2015.09.006","volume":"84","author":"C-H Lee","year":"2016","unstructured":"Lee C-H, Lee C-C, Hsieh C-C, Hong M-Y, Chi C-H. Predicting abscesses in adults with community-onset monomicrobial Enterobacteriaceae bacteremia: microorganisms matters. Diagn Microbiol Infect Dis. 2016;84:74\u20139. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2015.09.006.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02938-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:49:26Z","timestamp":1793645366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02938-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2938"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02938-0","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of the cohort, the ethic committee waived the need of informed consent to participate.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of the cohort, the ethic committee waived the need of informed consent to publish.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}